Anti-CD8 alpha depleting antibodies
AssigneePolygon Therapeutics
InventorsTatiana Monseur, Mohamed Abou Ali
Life of this patent
Estimating the term…
Abstract
Novel anti-CD8α (cluster of differentiation 8 alpha) antibodies and antigen-binding fragments thereof, a fusion protein including the anti-CD8α antibodies and antigen-binding fragments thereof, and a nucleic acid molecule encoding the anti-CD8α antibodies and antigen-binding fragments thereof. Also, pharmaceutical compositions including the anti-CD8α antibodies and antigen-binding fragments thereof. Further, methods using the anti-CD8α antibodies and antigen-binding fragments thereof for treating CD8-related diseases and in vitro methods in which CD8a-expressing cells are depleted in a sample or in which CD8α is detected or quantified in a sample.
Claims13
An isolated anti-CD8α antibody, or an antigen-binding fragment thereof, wherein:
- a) the variable region of the heavy chain (VH) of said isolated anti-CD8α antibody, or antigen-binding fragment thereof, comprises the three following CDRs:
- VH-CDR1:
- NX1X2MN, wherein
- X1 is N or Y,
- X2 is D or A or Y,
- VH-CDR2:
- X3ISGSSX4YIX5YADFVKG (SEQ ID NO:
- 1), wherein
- X3 is D or S,
- X4 is S or R,
- X5 is D or G or Y,
- VH-CDR3:
- SSX6X7X8X9YX10X11X12X13MDV (SEQ ID NO:
- 2), wherein
- X6 is N or no amino acid,
- X7 is Y or no amino acid,
- X8 is Y or G or no amino acid,
- X9 is D or S or no amino acid,
- X10 is S or N or F,
- X1 is A or G,
- X12 is S or D or N,
- X13 is A or G;
- and
- b) the variable region of the light chain (VL) of said isolated anti-CD8α antibody, or antigen-binding fragment thereof, comprises the three following CDRs:
- VL-CDR1:
- AGTSSDVGGX14X15X16VS (SEQ ID NO:
- 3), wherein
- X14 is G or N or Y,
- X15 is S or Y,
- X16 is S or Y,
- VL-CDR2:
- X17DSX18RPS (SEQ ID NO:
- 4), wherein
- X17 is Q or S or Y,
- X18 is Y or S,
- VL-CDR3:
- SSX19TX20YSTRV (SEQ ID NO:
- 5), wherein
- X19 is Y or D,
- X20 is Y or Q or S.
Dependencies are inferred from the claim text.